Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study

8 Oct 2024

Abstract excerpt

BACKGROUND: MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients' MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogeneity within MYC(N)-amplified MB and determined its relevance for improved disease management. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39377358
DOI: 10.1093/neuonc/noae178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort studyPMID 39377358Read ↗

Biological and clinical heterogeneity of MYCN-amplified medulloblastomaSemantic proximity Read ↗

Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in MedulloblastomaSemantic proximity Read ↗

Genetic and molecular alterations across medulloblastoma subgroups.Semantic proximity Read ↗

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastomaSemantic proximity Read ↗

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures.Semantic proximity Read ↗

Adult Medulloblastoma: Clinico-molecular Spectrum, An Institutional ExperienceSemantic proximity Read ↗

MYCN amplification defines an aggressive phenotype in IDH-mutant gliomas.Semantic proximity Read ↗

Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified ApproachSemantic proximity Read ↗

Adult Medulloblastoma Comprises Three Major Molecular VariantsSemantic proximity Read ↗

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.Semantic proximity Read ↗

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.